期刊文献+

EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis 被引量:3

EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis
下载PDF
导出
摘要 Apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand(TRAIL) can be regulated by the epidermal growth factor(EGF) signaling pathway.In this study,recombinant adenoviral vectors that encode TRAIL gene from the hTERT/RGD promoter(AdTRAIL) was combined with drugs including gefitinib,elotinib,and cetuximab that inhibit EGFR and the EGF signaling pathway in non-small cell lung cancer(NSCLC) cell lines to investigate their antitumor activity.In vitro,compared to single reagent,AdTRAIL combined with EGFR inhibitors reduced proliferation and enhanced apoptosis in H460,A549,and SW1573 cell lines.Western blot results suggested that these effects were relative to up-regulation of pro-apoptosis protein BAX and down-regulation of p-AKT.In vivo,AdTRAIL combined with cetuximab resulted in a significant growth reduction in H460 xenografts without damage to the main organs of nude mice.Histological examination and TUNEL analyses of xenografts showed that cetuximab enhanced cell apoptosis induced by AdTRAIL.These results indicate that EGFR inhibitors enhanced AdTRAIL anti-tumor activity in NSCLC cell lines and that inhibiting the AKT pathway played an important role in this enhancement. Apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can be regulated by the epidermal growth factor (EGF) signaling pathway. In this study, recombinant adenoviral vectors that encode TRAIL gene from the hTERT/RGD, promoter (AdTRAIL) was combined with drugs including gefitinib, elotinib, and cetuximab that inhibit EGFR and the EGF signaling pathway in non-small cell lung cancer (NSCLC) cell lines to investigate their antitumor activity. In vitro, compared to single reagent, AdTRAIL combined with EGFR inhibitors reduced proliferation and enhanced apoptosis in H460, A549, and SW1573 cell lines. Western blot results suggested that these effects were relative to up- regulation of pro-apoptosis protein BAX and down-regulation of p-AKT. In vivo, AdTRAIL combined with cetuximab resulted in a significant growth reduction in H460 xenografts without damage to the main organs of nude mice. Histological examination and TUNEL analyses of xenografts showed that cetuximab enhanced cell apoptosis induced by AdTRAIL. These results indicate that EGFR inhibitors enhanced AdTRAIL anti-tumor activity in NSCLC cell lines and that inhibiting the AKT pathway played an important role in this enhancement.
出处 《Chinese Journal of Cancer》 SCIE CAS CSCD 北大核心 2011年第10期701-711,共11页
关键词 肿瘤坏死因子相关凋亡诱导配体 细胞凋亡 TRAIL EGFR 抑制剂 肺癌细胞 表皮生长因子受体 非小细胞肺癌 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), epidermal growth factor receptor (EGFR), gene therapy, target therapy, non-small cell lung cancer
  • 相关文献

参考文献34

  • 1Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2- neu mRNA expression in non-small cell lung cancer is correlated with survival [J]. Clin Cancer Res, 2001,7(7):1850-1855.
  • 2Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor- related growth factors and receptors and of neoangiogenesis in completely resected stage I -IIIA non- small- cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival [J]. Clin Cancer Res, 1998,4(1):241-249.
  • 3Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression [J]. Clin Cancer Res, 1997,3(4):515-522.
  • 4Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors [J]. Semin Oncol, 2003,30(1 Suppl 1):3-11.
  • 5Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non -small- cell lung cancer (FLEX): an open- label randomised phase III trial [J]. Lancet, 2009,373(9674):1525-1531.
  • 6Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin, with or without cetuximab, as first- line therapy for patients with advanced or metastatic non small- cell lung cancer [J]. J Clin Oncol, 2007,25(36):5777-5784.
  • 7Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first- line therapy in EGFR-expressing advanced non -small- cell lung cancer [J]. Ann Oncol, 2008,19(2):362-369.
  • 8Fukuoka M, Yano S, Giaccone G, et al. Multi- institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small- cell lung cancer (The IDEAL 1 Trial) [J]. J Clin Oncol, 2003,21(12):2237-2246.
  • 9Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non -small cell lung cancer: a randomized trial [J]. JAMA, 2003,290 (16):2149 - 2158.
  • 10Niho S, Kubota K, Goto K, et al. First- line single agent treatment with gefitinib in patients with advanced non-small- cell lung cancer: a phase II study [J]. J Clin Oncol, 2006,24(1): 64-69.

同被引文献26

引证文献3

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部